Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PhotoCure ASAFRA:PHS +0.39%70 Equity-to-Asset is 0.74 as of Mar. 2026, which is 6% above its 10-year median of 0.70. GuruFocus rates FRA:PHS with a GF Score™ of 70/100 and a GF Value™ of €6.29 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 1,006 Drug Manufacturers companies, PhotoCure ASA ranks better than 70.87% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. PhotoCure ASA's Total Stockholders Equity for the quarter that ended in Mar. 2026 was €51.76 Mil. PhotoCure ASA's Total Assets for the quarter that ended in Mar. 2026 was €70.40 Mil.
Therefore, PhotoCure ASA's Equity to Asset Ratio for the quarter that ended in Mar. 2026 was 0.74.
The historical rank and industry rank for PhotoCure ASA's Equity-to-Asset or its related term are showing as below:
FRA:PHS'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.64 Med: 0.7 Max: 0.91
Current: 0.74
During the past 13 years, the highest Equity to Asset Ratio of PhotoCure ASA was 0.91. The lowest was 0.64. And the median was 0.70.
FRA:PHS's Equity-to-Asset is ranked better than 70.87% of 1006
companies
in the Drug Manufacturers industry
Industry Median: 0.61
vs FRA:PHS: 0.74
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
PhotoCure ASA Equity-to-Asset Related Terms
PhotoCure ASA Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for PhotoCure ASA's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:PHS vs ZTS, UTHR, VTRS: Equity-to-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, PhotoCure ASA's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PhotoCure ASA Equity-to-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, PhotoCure ASA's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where PhotoCure ASA's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
PhotoCure ASA's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PhotoCure ASA (FRA:PHS) has a Equity-to-Asset of 0.74 as of Mar. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on PhotoCure ASA and its competitors. This is near median its historical median of 0.70. Over the past decade, PhotoCure ASA's Equity-to-Asset has ranged from 0.64 to 0.91. According to the industry distribution chart, PhotoCure ASA ranks #293 out of 1006 companies in the Drug Manufacturers industry, placing it in the top 29.1%.
Is PhotoCure ASA's Equity-to-Asset too high?
PhotoCure ASA's current Equity-to-Asset of 0.74 is near median its 10-year median of 0.70. Over the past 10 years, this metric has ranged from a low of 0.64 to a high of 0.91. The Drug Manufacturers industry median Equity-to-Asset is 0.61. PhotoCure ASA's value of 0.74 is 21.3% above this industry median. Based on the distribution chart, PhotoCure ASA ranks #293 out of 1006 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, PhotoCure ASA has a GF Score™ of 70/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PhotoCure ASA's Equity-to-Asset compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, PhotoCure ASA ranks #293 out of 1006 companies for Equity-to-Asset. This puts PhotoCure ASA in the upper half of its industry. The industry median Equity-to-Asset is 0.61. PhotoCure ASA's value of 0.74 is 21.3% above this benchmark. Historically, PhotoCure ASA's own Equity-to-Asset has ranged from 0.64 to 0.91 over the past decade. While the company's 10-year median is 0.70 vs. the industry median of 0.61, PhotoCure ASA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Drug Manufacturers company?
The median Equity-to-Asset among Drug Manufacturers companies is 0.61, based on 1,006 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PhotoCure ASA's current Equity-to-Asset of 0.74 is 21.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on PhotoCure ASA and its competitors. For the Drug Manufacturers industry, the median Equity-to-Asset is 0.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PhotoCure ASA's current Equity-to-Asset is 0.74, which is near median its own 10-year median of 0.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PhotoCure ASA stock overvalued right now?
Based on GuruFocus' analysis, PhotoCure ASA (FRA:PHS) is currently considered Modestly Undervalued. The stock's GF Value™ is €6.29, compared to a current price of €5.14 — trading 18.3% below its estimated fair value. The current Equity-to-Asset is 0.74, which is near median its 10-year median of 0.70 and 21.3% above the Drug Manufacturers industry median of 0.61. PhotoCure ASA's overall GF Score™ is 70/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For PhotoCure ASA (FRA:PHS), the current Equity-to-Asset is 0.74 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PhotoCure ASA (FRA:PHS) Overvalued in 2026?
Based on GuruFocus' analysis, PhotoCure ASA stock appears to be undervalued.
The current stock price of €5.14 is trading 18.3% below its estimated GF Value™ of €6.29.
GuruFocus considers PhotoCure ASA to be Modestly Undervalued.
Key valuation signals for FRA:PHS:
Equity-to-Asset: 0.74 (near median its 10-year median of 0.70)
GF Value™: €6.29 vs. price of €5.14 (18.3% below fair value)
Industry Position: 21.3% above the Drug Manufacturers median (#293 of 1006)
No single metric tells the full story. See the FRA:PHS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PhotoCure ASA is a Norway-based business group associated with the research, development, production, distribution, marketing, and sales of pharmaceutical products and specialty pharmaceutical companies. The technology platform of the company is focused on the field of photodynamic diagnosis and treatment of cancer. The company has two operating segments of the group the Commercial franchise and the Development portfolio. It generates prime revenue from the Commercial franchise segment, which includes Hexvix and Cysview products. Its geographical segments are Nordic countries, Germany, France, Austria, the United Kingdom, BeNeLux, Italy, Other European countries, Canada, and the United States.
70GF Score
Get the complete analysis for FRA:PHS
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:PHS has been successfully added to your 
